Aclaris Therapeutics (ACRS) Projected to Announce Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $1.23 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. The company had revenue of $1.63 million during the quarter, compared to the consensus estimate of $1.38 million. On average, analysts expect Aclaris Therapeutics to post ($0.62) EPS for the current fiscal year and ($0.64) EPS for the next fiscal year.

Aclaris Therapeutics Trading Up 4.5%

ACRS stock opened at $3.96 on Thursday. The firm has a market cap of $553.69 million, a P/E ratio of -6.83 and a beta of 0.87. Aclaris Therapeutics has a 1-year low of $2.10 and a 1-year high of $6.60. The business’s 50 day moving average is $4.98 and its 200-day moving average is $4.50.

More Aclaris Therapeutics News

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: Aclaris reported positive Phase 1b proof-of-concept results for ATI-052, its anti-TSLP/IL-4R? bispecific candidate, in atopic dermatitis and asthma. The data provide early clinical support for the company’s immuno-inflammatory pipeline and could improve the program’s development prospects. Aclaris ATI-052 Phase 1b results
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $16 price target, implying substantial upside if Aclaris successfully advances ATI-052 and its broader pipeline. HC Wainwright rating
• Neutral Sentiment: Wedbush maintained an “outperform” rating but reduced its price target to $8 from $10. The target remains well above the current trading level, but the cut suggests more cautious near-term assumptions. Wedbush Aclaris price target
• Negative Sentiment: Aclaris priced a roughly $50 million underwritten offering consisting of 7.8 million common shares at $3.50 each and pre-funded warrants representing another 6.5 million shares. The financing strengthens the balance sheet and funds development, but the large potential increase in shares outstanding—and pricing below the market—dilutes existing shareholders and appears to be the main reason the stock declined despite the positive trial news. Aclaris $50 million offering

Wall Street Analyst Weigh In

Several research analysts have recently commented on ACRS shares. Canaccord Genuity Group began coverage on Aclaris Therapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $10.00 target price on the stock. Wall Street Zen raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Wedbush dropped their price target on Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Finally, Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a research report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $11.00.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.